Eagle Asset Management Inc. cut its stake in Zogenix (NASDAQ:ZGNX) by 0.2% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 992,170 shares of the company’s stock after selling 2,229 shares during the period. Eagle Asset Management Inc. owned 2.84% of Zogenix worth $39,736,000 at the end of the most recent quarter.
A number of other hedge funds also recently made changes to their positions in ZGNX. SG Americas Securities LLC bought a new stake in Zogenix in the first quarter valued at approximately $100,000. Neuburgh Advisers LLC bought a new stake in Zogenix in the first quarter valued at approximately $264,000. Tyers Asset Management LLC bought a new stake in Zogenix in the first quarter valued at approximately $337,000. Teacher Retirement System of Texas bought a new stake in Zogenix in the fourth quarter valued at approximately $409,000. Finally, Raymond James & Associates bought a new stake in Zogenix in the fourth quarter valued at approximately $460,000.
Zogenix stock opened at $41.25 on Monday. The company has a market cap of $1.45 billion, a price-to-earnings ratio of -10.26 and a beta of 1.70. Zogenix has a 52-week low of $10.05 and a 52-week high of $45.85.
Zogenix (NASDAQ:ZGNX) last posted its quarterly earnings results on Wednesday, May 9th. The company reported ($0.87) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.74) by ($0.13). During the same period in the previous year, the company posted ($0.86) earnings per share. sell-side analysts anticipate that Zogenix will post -3.89 earnings per share for the current fiscal year.
In other Zogenix news, Director Roger Hawley sold 35,000 shares of the stock in a transaction that occurred on Tuesday, March 13th. The stock was sold at an average price of $44.71, for a total transaction of $1,564,850.00. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. 5.00% of the stock is currently owned by corporate insiders.
ZGNX has been the topic of a number of research analyst reports. ValuEngine upgraded Zogenix from a “hold” rating to a “buy” rating in a report on Monday, April 2nd. Zacks Investment Research upgraded Zogenix from a “hold” rating to a “buy” rating and set a $50.00 price target on the stock in a report on Thursday, March 15th. Leerink Swann increased their price target on Zogenix from $50.00 to $54.00 and gave the stock an “outperform” rating in a report on Friday, February 23rd. Mizuho restated a “buy” rating and set a $51.00 price target on shares of Zogenix in a report on Thursday, February 1st. Finally, BidaskClub cut Zogenix from a “buy” rating to a “hold” rating in a report on Tuesday, April 10th. Seven analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average price target of $53.20.
Zogenix Company Profile
Zogenix, Inc, a pharmaceutical company, develops and commercializes therapies for the treatment of central nervous system disorders in the United States. Its lead product candidate is the ZX008, a low-dose fenfluramine, which is in Phase III clinical trials for the treatment of seizures associated with Dravet syndrome.
Want to see what other hedge funds are holding ZGNX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zogenix (NASDAQ:ZGNX).
Receive News & Ratings for Zogenix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zogenix and related companies with MarketBeat.com's FREE daily email newsletter.